Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026)

Stoke Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 17.07% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $14.2 million (up 6.94% YoY), while the FY2025 annual figure was $13.7 million, up 10.6% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.4 million, down from $3.6 million in the prior quarter.
• The five-year high for Non Operating Income was $3.8 million in Q2 2025, with the low at $104000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.7 million (2023), against an average of $2.5 million.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 4082.35% in 2022, then dropped 6.85% in 2024.
• Stoke Therapeutics' Non Operating Income stood at $1.4 million in 2022, then surged by 94.09% to $2.6 million in 2023, then climbed by 20.66% to $3.2 million in 2024, then increased by 12.39% to $3.6 million in 2025, then retreated by 4.18% to $3.4 million in 2026.
• Business Quant data shows STOK's Non Operating Income at $3.4 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.